Handbook of Anticancer Pharmacokinetics and Pharmacodynamics

  • Michelle A. Rudek
  • Cindy H. Chau
  • William D. Figg
  • Howard L. McLeod

Part of the Cancer Drug Discovery and Development book series (CDD&D)

Table of contents

  1. Front Matter
    Pages i-ix
  2. Christina M. Annunziata, Phillip A. Dennis
    Pages 1-21
  3. Angelika M. Burger, Heinz-Herbert Fiebig
    Pages 23-38
  4. Tawnya C. McKee, Albert W. W. Van Wyk, Emily L. Whitson
    Pages 39-67
  5. Bo Gao, Heinz-Josef Klumpen, Howard Gurney
    Pages 69-87
  6. Shivaani Kummar, James H. Doroshow
    Pages 89-97
  7. Hilary Glen, Jim Cassidy
    Pages 99-105
  8. H. Thomas Karnes, Kumar A. Shah
    Pages 117-139
  9. Uday B. Dandamudi, Andrew Beelen, Lionel D. Lewis
    Pages 141-157
  10. Jing Li, Michelle A. Rudek
    Pages 159-171
  11. Satjit S. Brar, Joga Gobburu
    Pages 173-192
  12. Kenneth S. Bauer, Fatemeh Tavakkoli
    Pages 193-208
  13. Alex Sparreboom, Walter J. Loos
    Pages 209-227
  14. David Jamieson, Sally A. Coulthard, Alan V. Boddy
    Pages 229-254
  15. Yuichi Ando
    Pages 273-288
  16. Pierre Bohanes, Heinz-Josef Lenz
    Pages 289-332
  17. Eddie Reed, Teri L. Larkins, Cindy H. Chau, William D. Figg
    Pages 333-349
  18. Laurent P. Rivory
    Pages 351-371

About this book

Introduction

There are many steps on the road from discovery of an anticancer drug to securing its final approval by the Food and Drug Administration. In this thoroughly updated and expanded second edition of the Handbook of Anticancer Pharmacokinetics and Pharmacodynamics, leading investigators synthesize an invaluable overview of the experimental and clinical processes of anticancer drug development, creating a single indispensable reference that covers all the steps from the identification of cancer-specific molecular targets to screening techniques and the development and validation of bioanalytical methods to clinical trial design and all phases of clinical trials. The authors have included new material on phase 0 trials in oncology, organ dysfunction trials, drug formulations and their impact on anticancer drug PK/PD including strategies to improve drug delivery, pharmacogenomics and cancer therapy, high throughput platforms in drug metabolism and transport pharmacogenetics, imaging in drug development and nanotechnology in cancer.

Authoritative and up-to-date, Handbook of Anticancer Pharmacokinetics and Pharmacodynamics, 2nd Edition provides in one comprehensive and highly practical volume a detailed step-by-step guide to the successful design and approval of anticancer drugs.

  • Road map to anticancer drug development from discovery to NDA submission
  • Discussion of molecular targets and preclinical screening
  • Development and validation of bioanalytical methods
  • Chapters on clinical trial design and phase 0, I, II, III clinical trials
  • Pharmacokinetics, pharmacodynamics, pharmacogenomics, and pharmacogenetics of anticancer agents
  • Review of the drug development process from both laboratory and clinical perspectives
  • New technological advances in imaging, high throughput platforms, and nanotechnology in anticancer drug development

Keywords

Cancer Pharmacodynamics Pharmacogenetics Pharmacokinetics Pharmacology

Editors and affiliations

  • Michelle A. Rudek
    • 1
  • Cindy H. Chau
    • 2
  • William D. Figg
    • 3
  • Howard L. McLeod
    • 4
  1. 1.Sidney Kimmel Comprehensive Cancer CenteBaltimoreUSA
  2. 2.Center for Cancer Research, National Cancer InstituteBethesdaUSA
  3. 3.Center for Cancer Research, National Cancer InstituteBethesdaUSA
  4. 4.Moffitt Cancer CenterTampaUSA

Bibliographic information

  • DOI https://doi.org/10.1007/978-1-4614-9135-4
  • Copyright Information Springer Science+Business Media New York 2014
  • Publisher Name Springer, New York, NY
  • eBook Packages Medicine
  • Print ISBN 978-1-4614-9134-7
  • Online ISBN 978-1-4614-9135-4
  • Series Print ISSN 2196-9906
  • Series Online ISSN 2196-9914
  • About this book